Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of GlaxoSmithKline Biologicals Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.

    Summary
    EudraCT number
    		 2015-001030-16
    Trial protocol
    		 Outside EU/EEA  
    Global end of trial date
    11 Jun 2015

    Results information
    Results version number
    		 v2
    This version publication date
    14 Oct 2017
    First version publication date
    24 Jun 2016
    Other versions
    		 v1 , v3
    Version creation reason
    • New data added to full data set
    New data added to full data set

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    205232
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT02285777
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline Biologicals
    Sponsor organisation address
    Rue de l’Institut 89, Rixensart, Belgium, B-1330
    Public contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
    Scientific contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    20 Jun 2017
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    26 Mar 2015
    Global end of trial reached?
    Yes
    Global end of trial date
    11 Jun 2015
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the effectiveness of the MenABCWY vaccine against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains as measured by bactericidal activity at 1:4 dilution using enc-hSBA at one month after the 3-dose series, when compared to a single dose of MenACWY.
    Protection of trial subjects
    Standard immunization practices were observed and care was taken to administer the injection intramuscularly. As with all injectable vaccines, appropriate medical treatment and supervision was readily available in case of rare anaphylactic reactions following administration of the study vaccine. Epinephrine 1:1000 and diphenhydramine was available in case of any anaphylactic reactions. Care was taken to ensure that the vaccine is not injected into a blood vessel. The measures of safety used in this study are routine clinical procedures. They include a close vigilance for, and stringent reporting of, selected local and systemic adverse events routinely monitored in vaccine clinical studies as indicators of reactogenicity. The period of observation for AEs extends from the time the subject signs informed consent until he or she completes the final study visit (Visit Month 4) or terminates the study early (whichever comes first).
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    01 Dec 2014
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 189
    Worldwide total number of subjects
    189
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    81
    Adolescents (12-17 years)
    97
    Adults (18-64 years)
    11
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 An Interactive Response Technology (IRT) will be used in the study. At Month 6 Visit of the parent study, IRT will allocate the study vaccines (either MenABCWY or placebo) to the subject. Subjects will receive either a 3rd dose of MenABCWY or one dose of a placebo, depending on their assigned vaccine group in parent study.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Carer, Assessor
    Blinding implementation details
    Trial is observer-blinded. Observer-blind means that during the course of study, the subject, the parents/guardians of the subjects and the study personnel responsible for the evaluation of any study endpoint (e.g. safety and reactogenicity) will be unaware which vaccine was administered. The vaccine preparation and administration will be done by designated medical personnel who will not participate in any of the clinical study evaluations.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 MenABCWY
    Arm description
    		 Subjects who received 2 doses of MenABCWY vaccine in the parent study, now receive a 3rd dose of MenABCWY vaccine in the current study.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine
    Investigational medicinal product code
    MenABCWY
    Other name
    Pharmaceutical forms
    Powder and solvent for solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 dose of 0.5 millilitres

    Arm title
    		 MenACWY
    Arm description
    		 Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study, now receive 1 dose of placebo in the current study.
    Arm type
    		 Active comparator

    Investigational medicinal product name
    Saline solution
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 dose of 0.5 millilitres

    Number of subjects in period 1
    		MenABCWY MenACWY
    Started
    95
    94
    Completed
    90
    91
    Not completed
    5
    3
         Consent withdrawn by subject
    1
    1
         Lost to follow-up
    4
    2

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    MenABCWY
    Reporting group description
    		 Subjects who received 2 doses of MenABCWY vaccine in the parent study, now receive a 3rd dose of MenABCWY vaccine in the current study.

    Reporting group title
    MenACWY
    Reporting group description
    		 Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study, now receive 1 dose of placebo in the current study.

    Reporting group values
    		 MenABCWY MenACWY Total
    Number of subjects
    		 95 94 189
    Age categorical
    Units: Subjects
        In utero
    		 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0 0
        Newborns (0-27 days)
    		 0 0 0
        Infants and toddlers (28 days-23 months)
    		 0 0 0
        Children (2-11 years)
    		 36 45 81
        Adolescents (12-17 years)
    		 53 44 97
        Adults (18-64 years)
    		 6 5 11
        From 65-84 years
    		 0 0 0
        85 years and over
    		 0 0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 12.8 ( 2.36 ) 12.4 ( 2.4 ) -
    Gender categorical
    Units: Subjects
        Female
    		 40 33 73
        Male
    		 55 61 116
    Race/Ethnicity, Customized
    Units: Subjects
        American Indian or Alaska native
    		 0 2 2
        Asian
    		 1 0 1
        Black or African American
    		 16 21 37
        Native Hawaiian or Other Pacific Islander
    		 0 0 0
        White
    		 74 66 140
        Other
    		 4 5 9

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    MenABCWY
    Reporting group description
    		 Subjects who received 2 doses of MenABCWY vaccine in the parent study, now receive a 3rd dose of MenABCWY vaccine in the current study.

    Reporting group title
    MenACWY
    Reporting group description
    		 Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study, now receive 1 dose of placebo in the current study.

    Primary: Percentages of subjects without bactericidal activity at 1:4 dilution against each US Neisseria meningitidis (N. meningitidis) serogroup B strain at 1 month after the 3-dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of subjects without bactericidal activity at 1:4 dilution against each US Neisseria meningitidis (N. meningitidis) serogroup B strain at 1 month after the 3-dose vaccination series
    End point description
    The effectiveness of three doses of MenABCWY vaccine when compared to one dose of MenACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains at 1 month after the 3-dose vaccination series was evaluated in terms of: the combined percentage of subjects without bactericidal activity at 1:4 dilution using the human Serum Bactericidal Assay (hSBA) against each strain in MenABCWY group and MenACWY group. The data provided is an average of the percentage of subjects without bactericidal activity at 1:4 dilution across all 110 strains. Analysis was performed on FAS-Effectiveness (Month 7), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, received a subject ID and vaccination, and who provided evaluable serum sample with enc-hSBA result for at least one endemic N. meningitidis serogroup B invasive disease strain at Month 7.
    End point type
    Primary
    End point timeframe
    At Month 7 (1 month after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    93
    93
    Units: Percentage
    number (not applicable)
        Combined Endemic US Serogroup B Strains
    21.1
    73.7
    Statistical analysis title
    		 Vaccine Effectiveness at 1 month after Dose 3
    Statistical analysis description
    The Vaccine Effectiveness (VE) at 1 month after the 3-dose vaccination series for each strain is defined as [1 - (percentage of subjects without bactericidal activity at 1:4 dilution in MenABCWY group/percentage of subjects without bactericidal activity at 1:4 dilution in MenACWY group)] x 100. The combined VE across all strains was computed by mean of a generalized linear model.
    Comparison groups
    MenABCWY v MenACWY
    Number of subjects included in analysis
    186
    Analysis specification
    Pre-specified
    Analysis type
    		 other [1]
    P-value
    		 < 0.0001
    Method
    		 Generalized Linear Model
    Parameter type
    		 Vaccine Effectiveness
    Point estimate
    71
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 69
         upper limit
    		 73
    Notes
    [1] - In order to obtain the VE measure which is a measure based on the relative risk (RR), the BINOMIAL DISTRIBUTION and LOG LINK options were used in the generalized linear model to compute the log10 RR and the corresponding confidence interval.

    Secondary: Number of subjects reporting any solicited local or systemic Adverse Events (AEs)

    		 Close Top of page
    End point title
    		 Number of subjects reporting any solicited local or systemic Adverse Events (AEs)
    End point description
    Number of subjects reporting any solicited local or systemic AEs from Day 1 (6 hours) to Day 7 after any meningococcal vaccination is reported. Assessed solicited local symptoms were induration, erythema and pain. Assessed solicited general symptoms were fatigue, myalgia, arthralgia, headache, fever, chills and loss of appetite. Other solicited data included prevention of pain/fever and treatment of pain/fever. Any = occurrence of the symptom regardless of intensity grade. The analysis was performed on the Safety Set (solicited AEs and other solicited reactions), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject’s assignment and treatment status in the study, received a subject ID and a study vaccination, and provided post-vaccination reactogenicity data.
    End point type
    Secondary
    End point timeframe
    Day 1 (6 hours) to Day 7 after vaccination
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    90
    87
    Units: Subjects
        Any (Vacc.1, N=90,87)
    62
    25
        Any Local Reactions (Vacc.1, N=90,87)
    60
    15
        Any Systemic Reactions (Vacc.1, N=90,87)
    27
    15
        Induration (mm) (Vacc.1, N=88,87)
    6
    0
        Erythema (mm) (Vacc.1, N=87,86)
    6
    0
        Pain (Vacc.1, N=88,87)
    59
    15
        Nausea (Vacc.1, N=87,87)
    5
    5
        Fatigue (Vacc.1, N=87,87)
    14
    11
        Myalgia (Vacc.1, N=87,85)
    13
    3
        Arthralgia (Vacc.1, N=86,85)
    9
    0
        Headache (Vacc.1, N=88,87)
    13
    9
        Fever (Vacc.1, N=90,85)
    0
    1
        Chills (Vacc.1, N=88,87)
    2
    3
        Loss of appetite (Vacc.1, N=88,87)
    3
    3
        Prevention of pain/fever (Vacc.1, N=85,84)
    0
    0
        Treatment of pain/fever (Vacc.1, N=85,84)
    12
    3
    No statistical analyses for this end point

    Secondary: Number of subjects reporting any unsolicited AEs

    		 Close Top of page
    End point title
    		 Number of subjects reporting any unsolicited AEs
    End point description
    The number of subjects reporting unsolicited AEs after any vaccination is reported. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. The analysis was performed on the Safety set (unsolicited AEs), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject’s assignment and treatment status in the study, received a subject ID and a study vaccination, and had post-vaccination unsolicited adverse event records.
    End point type
    Secondary
    End point timeframe
    Day 1 to Day 30 after any vaccination
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    93
    93
    Units: Subjects
        Any AEs
    14
    11
    No statistical analyses for this end point

    Secondary: Number of subjects reporting any serious adverse events (SAEs), medically-attended AEs and AEs leading to premature withdrawal

    		 Close Top of page
    End point title
    		 Number of subjects reporting any serious adverse events (SAEs), medically-attended AEs and AEs leading to premature withdrawal
    End point description
    The number of subjects reporting any SAEs, medically-attended AEs and AEs leading to premature withdrawal during the entire study period is reported. SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. The analysis was performed on the Safety Set (overall).
    End point type
    Secondary
    End point timeframe
    During the entire study period (from Day 0 up to Month 10)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    95
    94
    Units: Subjects
        Any SAEs (N=93,93)
    0
    0
        Any Medically Attended AEs (N=93,93)
    14
    20
        Any AEs leading to premature withdrawal (N=95,94)
    0
    0
    No statistical analyses for this end point

    Secondary: Percentages of subjects without bactericidal activity at 1:4 dilution against each US N. meningitidis serogroup B strain at 4 months after the 3-dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of subjects without bactericidal activity at 1:4 dilution against each US N. meningitidis serogroup B strain at 4 months after the 3-dose vaccination series
    End point description
    The effectiveness of three doses of MenABCWY vaccine when compared to one dose of MenACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains at 4 months after the 3-dose vaccination series was evaluated in terms of: the combined percentage of subjects without bactericidal activity at 1:4 dilution using the hSBA against each strain in MenABCWY group and MenACWY group. The data provided is an average of the percentage of subjects without bactericidal activity at 1:4 dilution across all 110 strains. Analysis was performed on FAS-Effectiveness (Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, received a subject ID and vaccination, and who provided evaluable serum sample with enc-hSBA result for at least one endemic N. meningitidis serogroup B invasive disease strain at Month 10.
    End point type
    Secondary
    End point timeframe
    At Month 10 (4 months after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    90
    90
    Units: Percentage
    number (not applicable)
        Combined Endemic US Serogroup B Strains
    33.9
    69.9
    Statistical analysis title
    		 Vaccine Effectiveness at 4 months after Dose 3
    Statistical analysis description
    The VE at 4 months after the 3-dose vaccination series for each strain is defined as [1 - (percentage of subjects without bactericidal activity at 1:4 dilution in MenABCWY group/percentage of subjects without bactericidal activity at 1:4 dilution in MenACWY group)] x 100. The combined VE across all strains was computed by mean of a generalized linear model.
    Comparison groups
    MenABCWY v MenACWY
    Number of subjects included in analysis
    180
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 < 0.0001 [2]
    Method
    		 Generalized Linear Model
    Parameter type
    		 Vaccine Effectiveness
    Point estimate
    51
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 48
         upper limit
    		 55
    Notes
    [2] - In order to obtain the VE measure which is a measure based on the relative risk (RR), the BINOMIAL DISTRIBUTION and LOG LINK options were used in the generalized linear model to compute the log10 RR and the corresponding confidence interval.

    Secondary: Percentages of subjects without bactericidal activity at 1:8 dilution against each US N. meningitidis serogroup B strain at 1 and 4 months after the 3-dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of subjects without bactericidal activity at 1:8 dilution against each US N. meningitidis serogroup B strain at 1 and 4 months after the 3-dose vaccination series
    End point description
    The effectiveness of three doses of MenABCWY vaccine when compared to one dose of MenACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains at 1 and 4 months after the 3-dose vaccination series were evaluated in terms of: the combined percentage of subjects without bactericidal activity at 1:8 dilution using the hSBA against each strain in MenABCWY group and MenACWY group. The data provided is an average of the percentage of subjects without bactericidal activity at 1:8 dilution across all 110 strains. Analysis was performed on FAS-Effectiveness (Month 7 and 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, received a subject ID and vaccination, and who provided evaluable serum sample with enc-hSBA result for at least one endemic N. meningitidis serogroup B invasive disease strain at Month 7 and 10.
    End point type
    Secondary
    End point timeframe
    At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    93
    93
    Units: Percentage
    number (not applicable)
        Combined Serogroup B Strains (Month 7) (N=93;93)
    36.9
    75.8
        Combined Serogroup B Strains (Month 10) (N=90;90)
    60.3
    79.6
    Statistical analysis title
    		 Vaccine Effectiveness at 1 month after Dose 3
    Statistical analysis description
    The VE at 1 month after the 3-dose vaccination series for each strain is defined as [1 - (percentage of subjects without bactericidal activity at 1:8 dilution in MenABCWY group/percentage of subjects without bactericidal activity at 1:8 dilution in MenACWY group)] x 100. The combined VE across all strains was computed by mean of a generalized linear model.
    Comparison groups
    MenABCWY v MenACWY
    Number of subjects included in analysis
    186
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 < 0.0001 [3]
    Method
    		 Generalized Linear Model
    Parameter type
    		 Vaccine Effectiveness
    Point estimate
    51
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 48
         upper limit
    		 54
    Notes
    [3] - In order to obtain the VE measure which is a measure based on the relative risk (RR), the BINOMIAL DISTRIBUTION and LOG LINK options were used in the generalized linear model to compute the log10 RR and the corresponding confidence interval.
    Statistical analysis title
    		 Vaccine Effectiveness at 4 months after Dose 3
    Statistical analysis description
    The VE at 4 months after the 3-dose vaccination series for each strain is defined as [1 - (percentage of subjects without bactericidal activity at 1:8 dilution in MenABCWY group/percentage of subjects without bactericidal activity at 1:8 dilution in MenACWY group)] x 100. The combined VE across all strains was computed by mean of a generalized linear model.
    Comparison groups
    MenABCWY v MenACWY
    Number of subjects included in analysis
    186
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 < 0.0001 [4]
    Method
    		 Generalized Linear Model
    Parameter type
    		 Vaccine Effectiveness
    Point estimate
    24
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 20
         upper limit
    		 28
    Notes
    [4] - In order to obtain the VE measure which is a measure based on the relative risk (RR), the BINOMIAL DISTRIBUTION and LOG LINK options were used in the generalized linear model to compute the log10 RR and the corresponding confidence interval.

    Secondary: Percentages of US N. meningitidis serogroup B strains killed at 1:4 and 1:8 dilutions at 1 and 4 months after the 3-dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of US N. meningitidis serogroup B strains killed at 1:4 and 1:8 dilutions at 1 and 4 months after the 3-dose vaccination series
    End point description
    The mean percentage of US N. meningitidis serogroup B strains killed by each subject, at 1:4 and 1:8 dilutions before the 3-dose vaccination series, at Month 6 (PRE) and at 1 and 4 months after the 3-dose vaccination series (Month 7 and Month 10). The analysis was performed on the FAS-Effectiveness (Month 6, Month 7 and Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject’s assignment and treatment status in the study, received a subject ID and a study vaccination, and provided evaluable serum sample with the enc-hSBA result for at least one endemic N. meningitidis serogroup B invasive disease strain before the 3-dose vaccination series (Month 6) and at one and four months after the 3-dose series (Month 7 and Month 10).
    End point type
    Secondary
    End point timeframe
    At Month 6 (before the 3-dose vaccination series) and at Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    93
    93
    Units: Percentage
    arithmetic mean (standard deviation)
        1:4, PRE (N=93;93)
    56.97 ( 18.134 )
    22.94 ( 17.764 )
        1:4, Month 7 (N=93;93)
    77.78 ( 10.041 )
    21.91 ( 16.885 )
        1:4, Month 10 (N=90;90)
    62.37 ( 15.976 )
    22.49 ( 17.094 )
        1:8, PRE (N=93;93)
    28.81 ( 17.086 )
    11.53 ( 11.705 )
        1:8, Month 7 (N=93;93)
    56.95 ( 14.389 )
    11.4 ( 11.266 )
        1:8, Month 10 (N=90;90)
    31.46 ( 19.434 )
    11.15 ( 10.774 )
    No statistical analyses for this end point

    Secondary: Percentages of subjects with enc-hSBA ≥ 1:4 and enc-hSBA ≥ 1:8 at 1 and 4 months after the 3-dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of subjects with enc-hSBA ≥ 1:4 and enc-hSBA ≥ 1:8 at 1 and 4 months after the 3-dose vaccination series
    End point description
    The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY vaccine, in terms of percentages of subjects with enc-hSBA ≥ 1:4 and enc-hSBA ≥ 1:8 against four N. meningitidis serogroup B test strains (M14459, M07-0241084, 96217 and NZ98/254) at 1 and 4 months after the 3-dose vaccination series (Month 7 and Month 10). The analysis was performed on the FAS-Immunogenicity (Month 7 and Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject’s assignment and treatment status in the study, received a subject ID and a study vaccination, and provided evaluable serum samples at one and four months post-third vaccination (Month 7 and Month 10) and whose immunogenicity assay result was available for at least one serogroup B test strain.
    End point type
    Secondary
    End point timeframe
    At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    91
    90
    Units: Percentage
    number (confidence interval 95%)
        M14459 (≥ 1:4, Month 7) (N=91;90)
    98 (92.3 to 99.73)
    12 (6.3 to 20.8)
        M14459 (≥ 1:4, Month 10) (N=87;90)
    72 (61.8 to 81.5)
    12 (6.3 to 20.8)
        M14459 (≥ 1:8, Month 7) (N=91;90)
    67 (56.4 to 76.5)
    2 (0.27 to 7.8)
        M14459 (≥ 1:8, Month 10) (N=87;90)
    21 (12.7 to 30.7)
    1 (0.03 to 6)
        M07-0241084 (≥ 1:4, Month 7) (N=90;85)
    81 (71.5 to 88.6)
    21 (13.1 to 31.4)
        M07-0241084 (≥ 1:4, Month 10) (N=79;78)
    46 (34.3 to 57.2)
    22 (13.2 to 32.6)
        M07-0241084 (≥ 1:8, Month 7) (N=90;85)
    38 (27.8 to 48.6)
    5 (1.3 to 11.6)
        M07-0241084 (≥ 1:8, Month 10) (N=79;78)
    11 (5.3 to 20.5)
    6 (2.1 to 14.3)
        96217 (≥ 1:4, Month 7) (N=89;88)
    99 (93.9 to 99.97)
    48 (37 to 58.6)
        96217 (≥ 1:4, Month 10) (N=87;88)
    100 (95.8 to 100)
    41 (30.5 to 51.9)
        96217 (≥ 1:8, Month 7) (N=89;88)
    99 (93.9 to 99.97)
    17 (9.9 to 26.6)
        96217 (≥ 1:8, Month 10) (N=87;88)
    99 (93.8 to 99.97)
    16 (9 to 25.2)
        NZ98/254 (≥ 1:4, Month 7) (N=84;87)
    76 (65.7 to 84.8)
    1 (0.03 to 6.2)
        NZ98/254 (≥ 1:4, Month 10) (N=80;83)
    34 (23.6 to 45.2)
    1 (0.03 to 6.5)
        NZ98/254 (≥ 1:8, Month 7) (N=84;87)
    39 (28.8 to 50.5)
    1 (0.03 to 6.2)
        NZ98/254 (≥ 1:8, Month 10) (N=80;83)
    4 (0.8 to 10.6)
    0 (0 to 4.3)
    No statistical analyses for this end point

    Secondary: HT-hSBA Geometric Mean Titers (GMTs) against the N. meningitidis serogroup B test strains

    		 Close Top of page
    End point title
    		 HT-hSBA Geometric Mean Titers (GMTs) against the N. meningitidis serogroup B test strains
    End point description
    The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY vaccine, in terms of HT-hSBA GMTs against four N. meningitidis serogroup B test strains (M14459, M07-0241084, 96217 and NZ98/254) after the 3-dose vaccination series. The analysis was performed on the FAS-Immunogenicity (Month 7 and Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject’s assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at one and four months post-third vaccination (Month 7 and Month 10) and whose immunogenicity assay result was available for at least one serogroup B test strain.
    End point type
    Secondary
    End point timeframe
    At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    91
    91
    Units: Titers
    geometric mean (confidence interval 95%)
        M14459, Month 7 (N=91;88)
    23.12 (20 to 27)
    1.1 (0.94 to 1.29)
        M14459, Month 10 (N=88;91)
    3.93 (3.14 to 4.91)
    1.18 (0.95 to 1.46)
        M07-0241084, Month 7 (N=89;90)
    12.26 (9.59 to 16)
    1.74 (1.37 to 2.2)
        M07-0241084, Month 10 (N=86;90)
    3.04 (2.36 to 3.92)
    1.68 (1.31 to 2.14)
        96217, Month 7 (N=90;87)
    367.29 (277 to 486)
    4.02 (3.03 to 5.32)
        96217, Month 10 (N=87;85)
    142.06 (105 to 191)
    3.32 (2.46 to 4.48)
        NZ98/254, Month 7 (N=89;89)
    19.69 (16 to 24)
    1.02 (0.85 to 1.23)
        NZ98/254, Month 10 (N=87;90)
    3.75 (3.01 to 4.68)
    1.04 (0.84 to 1.29)
    No statistical analyses for this end point

    Secondary: Percentages of subjects with HT-hSBA titers against N. meningitidis serogroup B test strains ≥ Lower Limit of Quantitation (LLQ) at 1 month after the 3-dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of subjects with HT-hSBA titers against N. meningitidis serogroup B test strains ≥ Lower Limit of Quantitation (LLQ) at 1 month after the 3-dose vaccination series
    End point description
    The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of percentages of subjects with HT-hSBA titers ≥ LLQ (≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128) against serogroup N. meningitidis B test strains (M14459, M07-0241084, 96217 and NZ98/254), at 1 month after the 3-dose vaccination series. The analysis was performed on the FAS-Immunogenicity (Month 7), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject’s assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at one month post-third vaccination (Month 7) and whose immunogenicity assay result was available for at least one serogroup B test strain.
    End point type
    Secondary
    End point timeframe
    At Month 7 (1 month after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    91
    90
    Units: Percentage
    number (confidence interval 95%)
        M14459, ≥ 5 (N=91;88)
    95 (87.6 to 98.2)
    1 (0.03 to 6.2)
        M14459, ≥ 8 (N=91;88)
    90 (82.1 to 95.4)
    1 (0.03 to 6.2)
        M14459, ≥ 16 (N=91;88)
    71 (61 to 80.4)
    1 (0.03 to 6.2)
        M14459, ≥ 32 (N=91;88)
    34 (24.5 to 44.7)
    1 (0.03 to 6.2)
        M14459, ≥ 64 (N=91;88)
    11 (5.4 to 19.3)
    0 (0 to 4.1)
        M14459, ≥ 128 (N=91;88)
    3 (0.7 to 9.3)
    0 (0 to 4.1)
        M07-0241084, ≥ 5 (N=89;90)
    82 (72.5 to 89.4)
    16 (8.8 to 24.7)
        M07-0241084, ≥ 8 (N=89;90)
    67 (56.7 to 77)
    12 (6.3 to 20.8)
        M07-0241084, ≥ 16 (N=89;90)
    46 (35.4 to 57)
    8 (3.2 to 15.4)
        M07-0241084, ≥ 32 (N=89;90)
    20 (12.4 to 30.1)
    3 (0.7 to 9.4)
        M07-0241084, ≥ 64 (N=89;90)
    6 (1.8 to 12.6)
    2 (0.27 to 7.8)
        M07-0241084, ≥ 128 (N=89;90)
    0 (0 to 4.1)
    0 (0 to 4)
        96217, ≥ 5 (N=90;87)
    100 (96 to 100)
    38 (27.7 to 49)
        96217, ≥ 8 (N=90;87)
    100 (96 to 100)
    37 (26.7 to 47.8)
        96217, ≥ 16 (N=90;87)
    100 (96 to 100)
    25 (16.6 to 35.7)
        96217, ≥ 32 (N=90;87)
    100 (96 to 100)
    15 (8.2 to 24.2)
        96217, ≥ 64 (N=90;87)
    99 (94 to 99.97)
    8 (3.3 to 15.9)
        96217, ≥ 128 (N=90;87)
    93 (86.1 to 97.5)
    3 (0.7 to 9.7)
        NZ98/254, ≥ 5 (N=89;89)
    89 (80.3 to 94.5)
    1 (0.03 to 6.1)
        NZ98/254, ≥ 8 (N=89;89)
    79 (68.7 to 86.6)
    1 (0.03 to 6.1)
        NZ98/254, ≥ 16 (N=89;89)
    61 (49.7 to 70.9)
    0 (0 to 4.1)
        NZ98/254, ≥ 32 (N=89;89)
    37 (27.1 to 48)
    0 (0 to 4.1)
        NZ98/254, ≥ 64 (N=89;89)
    10 (4.7 to 18.3)
    0 (0 to 4.1)
        NZ98/254, ≥ 128 (N=89;89)
    4 (1.2 to 11.1)
    0 (0 to 4.1)
    No statistical analyses for this end point

    Secondary: Percentages of subjects with HT-hSBA titers against N. meningitidis serogroup B test strains ≥ LLQ at 4 months after the 3-dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of subjects with HT-hSBA titers against N. meningitidis serogroup B test strains ≥ LLQ at 4 months after the 3-dose vaccination series
    End point description
    The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of percentages of subjects with HT-hSBA titers ≥ LLQ (≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128) against serogroup N. meningitidis B test strains (M14459, M07-0241084, 96217 and NZ98/254), at 4 months after the 3-dose vaccination series. The analysis was performed on the FAS - Immunogenicity (Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject’s assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at four months post-third vaccination (Month 10) and whose immunogenicity assay result was available for at least one serogroup B test strain.
    End point type
    Secondary
    End point timeframe
    At Month 10 (4 months after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    88
    91
    Units: Percentage
    number (confidence interval 95%)
        M14459, ≥ 5 (N=88;91)
    49 (38.1 to 59.8)
    4 (1.2 to 10.9)
        M14459, ≥ 8 (N=88;91)
    36 (26.4 to 47.3)
    3 (0.7 to 9.3)
        M14459, ≥ 16 (N=88;91)
    17 (9.9 to 26.6)
    1 (0.03 to 6)
        M14459, ≥ 32 (N=88;91)
    6 (1.9 to 12.8)
    0 (0 to 4)
        M14459, ≥ 64 (N=88;91)
    1 (0.03 to 6.2)
    0 (0 to 4)
        M14459, ≥ 128 (N=88;91)
    0 (0 to 4.1)
    0 (0 to 4)
        M07-0241084, ≥ 5 (N=86;90)
    38 (28.1 to 49.5)
    17 (9.6 to 26)
        M07-0241084, ≥ 8 (N=86;90)
    24 (15.8 to 34.9)
    12 (6.3 to 20.8)
        M07-0241084, ≥ 16 (N=86;90)
    9 (4.1 to 17.5)
    9 (3.9 to 16.8)
        M07-0241084, ≥ 32 (N=86;90)
    1 (0.03 to 6.3)
    3 (0.7 to 9.4)
        M07-0241084, ≥ 64 (N=86;90)
    1 (0.03 to 6.3)
    2 (0.27 to 7.8)
        M07-0241084, ≥ 128 (N=86;90)
    0 (0 to 4.2)
    1 (0.03 to 6)
        96217, ≥ 5 (N=87;85)
    99 (93.8 to 99.97)
    35 (25.2 to 46.4)
        96217, ≥ 8 (N=87;85)
    99 (93.8 to 99.97)
    33 (23.1 to 44)
        96217, ≥ 16 (N=87;85)
    98 (91.9 to 99.72)
    21 (13.1 to 31.4)
        96217, ≥ 32 (N=87;85)
    94 (87.1 to 98.1)
    16 (9.3 to 26.1)
        96217, ≥ 64 (N=87;85)
    85 (75.8 to 91.8)
    6 (1.9 to 13.2)
        96217, ≥ 128 (N=87;85)
    56 (45.3 to 66.9)
    2 (0.29 to 8.2)
        NZ98/254, ≥ 5 (N=87;90)
    44 (33.1 to 54.7)
    1 (0.03 to 6)
        NZ98/254, ≥ 8 (N=87;90)
    34 (24.6 to 45.4)
    1 (0.03 to 6)
        NZ98/254, ≥ 16 (N=87;90)
    16 (9.1 to 25.5)
    0 (0 to 4)
        NZ98/254, ≥ 32 (N=87;90)
    5 (1.3 to 11.4)
    0 (0 to 4)
        NZ98/254, ≥ 64 (N=87;90)
    2 (0.28 to 8.1)
    0 (0 to 4)
        NZ98/254, ≥ 128 (N=87;90)
    2 (0.28 to 8.1)
    0 (0 to 4)
    No statistical analyses for this end point

    Secondary: Percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series
    End point description
    The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains, at 1 and 4 months after the 3-dose vaccination series. The four-fold titers rise is defined as: a) for subjects with pre-vaccination HT-hSBA titers < LLQ, post-vaccination HT-hSBA titers ≥ 4 LLQ; b) for subjects with pre-vaccination HT-hSBA titers ≥ LLQ, an increase of at least four times the pre-vaccination HT-hSBA titers. The analysis was performed on the FAS-Immunogenicity (Month 7 and Month 10).
    End point type
    Secondary
    End point timeframe
    At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    0 [5]
    0 [6]
    Units: Percentage
        number (confidence interval 95%)
    ( to )
    ( to )
    Notes
    [5] - The results will be updated when they become available.
    [6] - The results will be updated when they become available.
    No statistical analyses for this end point

    Secondary: HT-hSBA GMTs against N. meningitidis serogroups A, C, W and Y

    		 Close Top of page
    End point title
    		 HT-hSBA GMTs against N. meningitidis serogroups A, C, W and Y
    End point description
    The immunogenicity of three doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of HT-hSBA GMTs to serogroups A, C, W, and Y, at 1 and 4 months after the 3-dose vaccination series. The analysis was performed on the FAS-Immunogenicity (Month 7 and Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject’s assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at one and four months post-third vaccination (Month 7 and Month 10) and whose immunogenicity assay result was available for at least one serogroup A, C, W and Y test strain.
    End point type
    Secondary
    End point timeframe
    At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    91
    91
    Units: Titers
    geometric mean (confidence interval 95%)
        Men A, Month 7 (N=91;87)
    127.92 (91 to 179)
    3.37 (2.41 to 4.73)
        Men A, Month 10 (N=85;88)
    36.5 (25 to 53)
    2.73 (1.89 to 3.94)
        Men C, Month 7 (N=85;86)
    521.64 (365 to 745)
    18.34 (13 to 26)
        Men C, Month 10 (N=86;89)
    291.19 (201 to 421)
    15.4 (11 to 22)
        Men W, Month 7 (N=83;88)
    424.8 (310 to 581)
    40.22 (30 to 54)
        Men W, Month 10 (N=85;83)
    147.4 (104 to 209)
    23.01 (16 to 33)
        Men Y, Month 7 (N=91;88)
    204.84 (142 to 296)
    13.27 (9.21 to 19)
        Men Y, Month 10 (N=86;91)
    83.42 (55 to 126)
    11.85 (7.93 to 18)
    No statistical analyses for this end point

    Secondary: Percentages of subjects with HT-hSBA titers against the N. meningitidis serogroup A, C, W and Y ≥ LLQ at 1 month after the 3- dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of subjects with HT-hSBA titers against the N. meningitidis serogroup A, C, W and Y ≥ LLQ at 1 month after the 3- dose vaccination series
    End point description
    The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ LLQ (≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥128) against serogroups A, C, W, Y, at 1 month after the 3-dose vaccination series. The analysis was performed on the FAS-Immunogenicity (Month 7), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject’s assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at one month post-third vaccination (Month 7) and whose immunogenicity assay result was available for at least one serogroup A, C, W and Y test strain.
    End point type
    Secondary
    End point timeframe
    At Month 7 (1 month after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    91
    88
    Units: Percentage
    number (confidence interval 95%)
        Men A, ≥ 8 (N=91;87)
    98 (92.3 to 99.73)
    30 (20.5 to 40.6)
        Men A, ≥ 16 (N=91;87)
    98 (92.3 to 99.73)
    26 (17.6 to 37)
        Men A, ≥ 32 (N=91;87)
    98 (92.3 to 99.73)
    22 (13.7 to 32)
        Men A, ≥ 64 (N=91;87)
    86 (76.8 to 92.2)
    13 (6.5 to 21.5)
        Men A, ≥ 128 (N=91;87)
    56 (45.2 to 66.4)
    8 (3.3 to 15.9)
        Men C, ≥ 8 (N=85;86)
    100 (95.8 to 100)
    71 (60.1 to 80.2)
        Men C, ≥ 16 (N=85;86)
    99 (93.6 to 99.97)
    51 (40.1 to 62.1)
        Men C, ≥ 32 (N=85;86)
    99 (93.6 to 99.97)
    33 (22.8 to 43.5)
        Men C, ≥ 64 (N=85;86)
    99 (93.6 to 99.97)
    26 (16.8 to 36.1)
        Men C, ≥ 128 (N=85;86)
    91 (82.3 to 95.8)
    19 (11 to 28.4)
        Men W, ≥ 8 (N=83;88)
    100 (95.7 to 100)
    86 (77.4 to 92.8)
        Men W, ≥ 16 (N=83;88)
    100 (95.7 to 100)
    77 (67.1 to 85.5)
        Men W, ≥ 32 (N=83;88)
    99 (93.5 to 99.97)
    61 (50.4 to 71.6)
        Men W, ≥ 64 (N=83;88)
    99 (93.5 to 99.97)
    45 (34.8 to 56.4)
        Men W, ≥ 128 (N=83;88)
    89 (80.4 to 94.9)
    24 (15.4 to 34.1)
        Men Y, ≥ 8 (N=91;88)
    100 (96 to 100)
    61 (50.4 to 71.6)
        Men Y, ≥ 16 (N=91;88)
    100 (96 to 100)
    56 (44.7 to 66.3)
        Men Y, ≥ 32 (N=91;88)
    95 (87.6 to 98.2)
    44 (33.7 to 55.3)
        Men Y, ≥ 64 (N=91;88)
    81 (71.8 to 88.7)
    27 (18.3 to 37.8)
        Men Y, ≥ 128 (N=91;88)
    65 (54.1 to 74.6)
    14 (7.2 to 22.6)
    No statistical analyses for this end point

    Secondary: Percentages of subjects with HT-hSBA titers against the N. meningitidis serogroup A, C, W and Y ≥ LLQ at 4 months after the 3-dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of subjects with HT-hSBA titers against the N. meningitidis serogroup A, C, W and Y ≥ LLQ at 4 months after the 3-dose vaccination series
    End point description
    The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ LLQ (≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128) against serogroups A, C, W, Y, at 4 months after the 3-dose vaccination series. The analysis was performed on the FAS-Immunogenicity (Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject’s assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at four months post-third vaccination (Month 10) and whose immunogenicity assay result was available for at least one serogroup A, C, W and Y test strain.
    End point type
    Secondary
    End point timeframe
    At Month 10 (4 months after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    86
    91
    Units: Percentage
    number (confidence interval 95%)
        Men A, ≥ 8 (N=85;88)
    86 (76.6 to 92.5)
    25 (16.4 to 35.4)
        Men A, ≥ 16 (N=85;88)
    84 (73.9 to 90.7)
    23 (14.5 to 32.9)
        Men A, ≥ 32 (N=85;88)
    72 (61 to 81)
    18 (10.8 to 27.8)
        Men A, ≥ 64 (N=85;88)
    46 (35 to 57)
    8 (3.3 to 15.7)
        Men A, ≥ 128 (N=85;88)
    14 (7.5 to 23.4)
    7 (2.5 to 14.3)
        Men C, ≥ 8 (N=86;89)
    100 (95.8 to 100)
    65 (54.3 to 75)
        Men C, ≥ 16 (N=86;89)
    98 (91.9 to 99.72)
    48 (37.6 to 59.2)
        Men C, ≥ 32 (N=86;89)
    97 (90.1 to 99.3)
    34 (24 to 44.5)
        Men C, ≥ 64 (N=86;89)
    86 (76.9 to 92.6)
    26 (17.1 to 36.2)
        Men C, ≥ 128 (N=86;89)
    74 (63.9 to 83.2)
    16 (8.9 to 25)
        Men W, ≥ 8 (N=85;83)
    99 (93.6 to 99.97)
    75 (64 to 83.6)
        Men W, ≥ 16 (N=85;83)
    98 (91.8 to 99.71)
    66 (55.1 to 76.3)
        Men W, ≥ 32 (N=85;83)
    94 (86.8 to 98.1)
    58 (46.5 to 68.6)
        Men W, ≥ 64 (N=85;83)
    75 (64.7 to 84)
    36 (25.9 to 47.4)
        Men W, ≥ 128 (N=85;83)
    52 (40.7 to 62.7)
    18 (10.5 to 28)
        Men Y, ≥ 8 (N=86;91)
    91 (82.5 to 95.9)
    58 (47.4 to 68.5)
        Men Y, ≥ 16 (N=86;91)
    86 (76.9 to 92.6)
    51 (39.9 to 61.2)
        Men Y, ≥ 32 (N=86;91)
    77 (66.4 to 85.2)
    38 (28.4 to 49.2)
        Men Y, ≥ 64 (N=86;91)
    62 (50.5 to 71.9)
    20 (12.2 to 29.4)
        Men Y, ≥ 128 (N=86;91)
    40 (29.2 to 50.7)
    9 (3.9 to 16.6)
    No statistical analyses for this end point

    Secondary: Percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series

    		 Close Top of page
    End point title
    		 Percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series
    End point description
    The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with two-, three- and four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains, at 1 and 4 months after the 3-dose vaccination series. The four-fold titers rise is defined as: a) for subjects with pre-vaccination HT-hSBA titers < LLQ, a post-vaccination HT-hSBA titers ≥ 4 LLQ; b) for subjects with pre-vaccination HT-hSBA titers ≥ LLQ, an increase of at least four times the pre-vaccination HT-hSBA titers. The analysis was performed on the FAS - Immunogenicity (Month 7 and Month 10).
    End point type
    Secondary
    End point timeframe
    At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)
    End point values
    		 MenABCWY MenACWY
    Number of subjects analysed
    0 [7]
    0 [8]
    Units: Percentage
        number (confidence interval 95%)
    ( to )
    ( to )
    Notes
    [7] - The results will be updated when they become available.
    [8] - The results will be updated when they become available.
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Solicited local and general symptoms: from Day 1 to Day 7. Unsolicited AEs: from Day 1 to Day 30. SAEs, medically-attended AEs and AEs leading to withdrawal: for the entire duration of the study (from Day 0 to Month 10).
    Adverse event reporting additional description
    Data are presented in terms of number of subjects reporting AEs.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    18.1
    Reporting groups
    Reporting group title
    MenABCWY
    Reporting group description
    		 Subjects who received 2 doses of MenABCWY vaccine in the parent study, now receive the 3rd dose of MenABCWY vaccine in the current study.

    Reporting group title
    MenACWY
    Reporting group description
    		 Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study, now receive 1 dose of placebo in the current study.

    Serious adverse events
    		 MenABCWY MenACWY
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 95 (0.00%)
    0 / 94 (0.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 MenABCWY MenACWY
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    67 / 95 (70.53%)
    42 / 94 (44.68%)
    Nervous system disorders
    Headache
         subjects affected / exposed [1]
    14 / 93 (15.05%)
    9 / 93 (9.68%)
         occurrences all number
    25
    27
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed [2]
    14 / 93 (15.05%)
    11 / 93 (11.83%)
         occurrences all number
    32
    24
    Injection site erythema
         subjects affected / exposed [3]
    16 / 93 (17.20%)
    4 / 93 (4.30%)
         occurrences all number
    44
    12
    Injection site induration
         subjects affected / exposed [4]
    16 / 93 (17.20%)
    3 / 93 (3.23%)
         occurrences all number
    57
    10
    Injection site pain
         subjects affected / exposed [5]
    60 / 93 (64.52%)
    15 / 93 (16.13%)
         occurrences all number
    155
    23
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed [6]
    5 / 93 (5.38%)
    5 / 93 (5.38%)
         occurrences all number
    9
    7
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed [7]
    9 / 93 (9.68%)
    1 / 93 (1.08%)
         occurrences all number
    21
    1
    Myalgia
         subjects affected / exposed [8]
    13 / 93 (13.98%)
    3 / 93 (3.23%)
         occurrences all number
    33
    10
    Infections and infestations
    Upper respiratory tract infection
         subjects affected / exposed [9]
    6 / 93 (6.45%)
    1 / 93 (1.08%)
         occurrences all number
    6
    1
    Notes
    [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.
    [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.
    [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.
    [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.
    [5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.
    [6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.
    [7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.
    [8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.
    [9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 27 05:13:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA